Glen Eagle Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $78.4K | Hold |
400
| – | – | 0.01% | 371 |
|
|
2025
Q4 | $69.4K | Hold |
400
| – | – | 0.01% | 385 |
|
|
2025
Q3 | $76.2K | Hold |
400
| – | – | 0.01% | 369 |
|
|
2025
Q2 | $71.9K | Hold |
400
| – | – | 0.01% | 365 |
|
|
2025
Q1 | $67.7K | Hold |
400
| – | – | 0.01% | 369 |
|
|
2024
Q4 | $60.3K | Sell |
400
-42
| -10% | -$6.53K | 0.01% | 382 |
|
|
2024
Q3 | $68.6K | Hold |
442
| – | – | 0.01% | 373 |
|
|
2024
Q2 | $60.5K | Hold |
442
| – | – | 0.01% | 372 |
|
|
2024
Q1 | $58.8K | Hold |
442
| – | – | 0.01% | 381 |
|
|
2023
Q4 | $60.9K | Hold |
442
| – | – | 0.01% | 359 |
|
|
2023
Q3 | $53.9K | Hold |
442
| – | – | 0.01% | 365 |
|
|
2023
Q2 | $62.1K | Hold |
442
| – | – | 0.01% | 351 |
|
|
2023
Q1 | $62.5K | Hold |
442
| – | – | 0.02% | 345 |
|
|
2022
Q4 | $69.1K | Sell |
442
-40
| -8% | -$5.75K | 0.02% | 324 |
|
|
2022
Q3 | $59.1K | Hold |
482
| – | – | 0.02% | 331 |
|
|
2022
Q2 | $64.1K | Hold |
482
| – | – | 0.02% | 333 |
|
|
2022
Q1 | $66K | Buy |
482
+40
| +9% | +$5.58K | 0.02% | 335 |
|
|
2021
Q4 | $76.5K | Hold |
442
| – | – | 0.02% | 315 |
|
|
2021
Q3 | $64.2K | Hold |
442
| – | – | 0.02% | 336 |
|
|
2021
Q2 | $58.3K | Hold |
442
| – | – | 0.02% | 354 |
|
|
2021
Q1 | $56.7K | Hold |
442
| – | – | 0.02% | 326 |
|
|
2020
Q4 | $52.7K | Hold |
442
| – | – | 0.02% | 319 |
|
|
2020
Q3 | $50.6K | Hold |
442
| – | – | 0.02% | 302 |
|
|
2020
Q2 | $50.4K | Hold |
442
| – | – | 0.03% | 286 |
|
|
2020
Q1 | $35.5K | Hold |
442
| – | – | 0.02% | 309 |
|
|
2019
Q4 | $47.2K | Hold |
442
| – | – | 0.03% | 319 |
|
|
2019
Q3 | $47.3K | Buy |
442
+1
| +0.2% | +$103 | 0.03% | 290 |
|
|
2019
Q2 | $44.9K | Buy |
441
+41
| +10% | +$3.94K | 0.03% | 288 |
|
|
2019
Q1 | $36K | Hold |
400
| – | – | 0.03% | 305 |
|
|
2018
Q4 | $33.3K | Hold |
400
| – | – | 0.03% | 286 |
|
|
2018
Q3 | $43.2K | Hold |
400
| – | – | 0.03% | 277 |
|
|
2018
Q2 | $44K | Hold |
400
| – | – | 0.03% | 267 |
|
|
2018
Q1 | $40.1K | Hold |
400
| – | – | 0.03% | 272 |
|
|
2017
Q4 | $39.4K | Sell |
400
-147
| -27% | -$13.9K | 0.03% | 265 |
|
|
2017
Q3 | $51.2K | Hold |
547
| – | – | 0.05% | 234 |
|
|
2017
Q2 | $60.8K | Buy |
547
+147
| +37% | +$15.5K | 0.05% | 202 |
|
|
2017
Q1 | $39.3K | Sell |
400
-200
| -33% | -$19.1K | 0.03% | 225 |
|
|
2016
Q4 | $55.1K | Buy |
+600
| New | +$51.7K | 0.05% | 189 |
|
Other funds holding DGX
VCM
VPM
EIG
Glen Eagle Advisors's DGX Position: Q1 2026 in Review
Glen Eagle Advisors held its Quest Diagnostics (DGX) position steady in Q1 2026 at 400 shares worth $78.4K. The position accounts for 0.01% of the portfolio, ranked #371.
Glen Eagle Advisors first reported a position in DGX in Q4 2016 and has held it in 38 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Glen Eagle Advisors held 400 shares of Quest Diagnostics worth $78.4K as of Q1 2026.
- Glen Eagle Advisors left its Quest Diagnostics share count unchanged in Q1 2026.
- Quest Diagnostics made up 0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #371 holding.
- Glen Eagle Advisors first reported a position in Quest Diagnostics in Q4 2016 and has held it in 38 quarters since.
- 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.